Emily Woodworth - 28 Feb 2025 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
SVP, Global Controller and CAO
Signature
/s/ Susan Thompson, Attorney-in-Fact
Issuer symbol
BSX
Transactions as of
28 Feb 2025
Net transactions value
-$732,407
Form type
4
Filing time
03 Mar 2025, 16:11:53 UTC
Previous filing
18 Feb 2025
Next filing
05 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $304,311 +7,218 +168% $42.16 11,519 28 Feb 2025 Direct F1
transaction BSX Common Stock Sale $999,872 -9,887 -86% $101.13 1,632 28 Feb 2025 Direct F1
transaction BSX Common Stock Options Exercise $0 +837 +51% $0.000000 2,469 01 Mar 2025 Direct F2
transaction BSX Common Stock Tax liability $36,845 -355 -14% $103.79 2,114 01 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Stock Option (Right to Buy) Options Exercise $0 -7,218 -100% $0.000000 0 28 Feb 2025 Common Stock 7,218 $42.16 Direct F1, F3
transaction BSX Restricted Stock Units Options Exercise $0 -837 -25% $0.000000 2,514 01 Mar 2025 Common Stock 837 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 29, 2024.
F2 Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F3 Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant.
F4 Shares of common stock will be issued to the reporting person in four equal annual installments beginning on March 1, 2025, the first anniversary of the date of grant.